# Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

> **NCT03624036** · PHASE1 · TERMINATED · sponsor: **Kite, A Gilead Company** · enrollment: 16 (actual)

## Conditions studied

- Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma

## Interventions

- **BIOLOGICAL:** brexucabtagene autoleucel
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03624036
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-15
- **Primary completion:** 2021-02-12
- **Final completion:** 2022-11-18
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Development program terminated
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03624036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03624036, "Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03624036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*